| Abstrakt: |
A recent study conducted by researchers at Tsinghua University in Beijing, China, focused on the development of an oral nanotherapeutic for the treatment of ulcerative colitis (UC). The researchers designed a nanotherapeutic agent called OPNs@LMWH, which demonstrated specific targeting effects and therapeutic efficacy. The agent was found to have high cellular uptake efficiency and preferentially accumulated in inflamed tissues. The study concluded that OPNs@LMWH effectively delivered treatment to inflamed sites, facilitating precise management of UC. [Extracted from the article] |
